Switch theme
Sign up to access all valuation multiples
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
1998
10.4K+
LTM Revenue $4.3B
LTM EBITDA $1.2B
$14.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Illumina has a last 12-month revenue (LTM) of $4.3B and a last 12-month EBITDA of $1.2B.
In the most recent fiscal year, Illumina achieved revenue of $4.4B and an EBITDA of -$725M.
Illumina expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Illumina valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.3B | XXX | $4.4B | XXX | XXX | XXX |
| Gross Profit | $2.9B | XXX | $2.9B | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 65% | XXX | XXX | XXX |
| EBITDA | $1.2B | XXX | -$725M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | -17% | XXX | XXX | XXX |
| EBIT | $920M | XXX | $600M | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $505M | XXX | -$1.2B | XXX | XXX | XXX |
| Net Margin | 12% | XXX | -28% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $862M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Illumina's stock price is $82.
Illumina has current market cap of $13.0B, and EV of $14.4B.
See Illumina trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $14.4B | $13.0B | XXX | XXX | XXX | XXX | $4.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Illumina has market cap of $13.0B and EV of $14.4B.
Illumina's trades at 3.3x EV/Revenue multiple, and -19.8x EV/EBITDA.
Equity research analysts estimate Illumina's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Illumina has a P/E ratio of 25.8x.
See valuation multiples for Illumina and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $13.0B | XXX | $13.0B | XXX | XXX | XXX |
| EV (current) | $14.4B | XXX | $14.4B | XXX | XXX | XXX |
| EV/Revenue | 3.3x | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | 12.5x | XXX | -19.8x | XXX | XXX | XXX |
| EV/EBIT | 15.6x | XXX | 24.0x | XXX | XXX | XXX |
| EV/Gross Profit | 4.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 25.8x | XXX | -10.6x | XXX | XXX | XXX |
| EV/FCF | 16.9x | XXX | 20.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIllumina's last 12 month revenue growth is -1%
Illumina's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Illumina's rule of 40 is -14% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Illumina's rule of X is 25% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Illumina and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -1% | XXX | 0% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | -17% | XXX | XXX | XXX |
| EBITDA Growth | 1% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -14% | XXX | -17% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 25% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Epigenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| ToolGen | XXX | XXX | XXX | XXX | XXX | XXX |
| 4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
| Genus | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Illumina acquired XXX companies to date.
Last acquisition by Illumina was XXXXXXXX, XXXXX XXXXX XXXXXX . Illumina acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Illumina founded? | Illumina was founded in 1998. |
| Where is Illumina headquartered? | Illumina is headquartered in United States of America. |
| How many employees does Illumina have? | As of today, Illumina has 10.4K+ employees. |
| Who is the CEO of Illumina? | Illumina's CEO is Mr. Jacob Thaysen. |
| Is Illumina publicy listed? | Yes, Illumina is a public company listed on NAS. |
| What is the stock symbol of Illumina? | Illumina trades under ILMN ticker. |
| When did Illumina go public? | Illumina went public in 2000. |
| Who are competitors of Illumina? | Similar companies to Illumina include e.g. EZZ Life Science, Epigenomics, ToolGen, 4basebio. |
| What is the current market cap of Illumina? | Illumina's current market cap is $13.0B |
| What is the current revenue of Illumina? | Illumina's last 12 months revenue is $4.3B. |
| What is the current revenue growth of Illumina? | Illumina revenue growth (NTM/LTM) is -1%. |
| What is the current EV/Revenue multiple of Illumina? | Current revenue multiple of Illumina is 3.3x. |
| Is Illumina profitable? | Yes, Illumina is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Illumina? | Illumina's last 12 months EBITDA is $1.2B. |
| What is Illumina's EBITDA margin? | Illumina's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Illumina? | Current EBITDA multiple of Illumina is 12.5x. |
| What is the current FCF of Illumina? | Illumina's last 12 months FCF is $850M. |
| What is Illumina's FCF margin? | Illumina's last 12 months FCF margin is 20%. |
| What is the current EV/FCF multiple of Illumina? | Current FCF multiple of Illumina is 16.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
